Stay updated on Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page
- CheckyesterdayChange DetectedA site-wide funding/operating status notice has been added, and the site version has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check9 days agoChange DetectedThe page now shows a glossary option and includes meta-data updates: the 'Last Update Submitted that Met QC Criteria' label and a 'No FEAR Act Data' note were added, and the site revision updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No changes to study content or critical functionality were observed.SummaryDifference0.1%

- Check45 days agoChange DetectedAdded a Locations section highlighting Texas (Houston, MD Anderson Cancer Center) for the study, removed the old Texas Locations block and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check67 days agoChange DetectedThe page revision label was updated from v3.3.1 to v3.3.2; no study content or critical details were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study, and updated the revision to v3.3.1. Deleted wording stating that PubMed publications are automatically created by ClinicalTrials.gov with an identifier and may or may not be related to the study; revision updated from v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.